⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Official Title: A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Study ID: NCT04991480

Study Description

Brief Summary: This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART4215 that can be given safely to participants alone and in combination with talazoparib * Learn more about the side effects of ART4215 alone and in combination with talazoparib * Learn more about the effectiveness of ART4215 alone and in combination with talazoparib * Learn more about the effectiveness of ART4215 alone and in combination with niraparib

Detailed Description: This is an open-label Phase I/IIa study designed to evaluate ART4215, a new first-in-class investigational medicinal product that is a potent and selective inhibitor of deoxyribonucleic acid (DNA) polymerase (pol) theta. ART4215 is being developed as an oral anti-cancer agent for monotherapy treatment of patients with cancers that harbor defects in DNA repair and in combination with anticancer medicines that cause DNA damage.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Yale School of Medicine, New Haven, Connecticut, United States

Florida Cancer Specialists, Orlando, Florida, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Oklahoma University, Oklahoma City, Oklahoma, United States

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Tennessee Oncology, Nashville, Tennessee, United States

MD Anderson Cancer Center, Houston, Texas, United States

Sarah Cannon Research Institute, London, England, United Kingdom

Contact Details

Name: Erika Hamilton, MD

Affiliation: Tennessee Oncology

Role: STUDY_CHAIR

Name: Timothy Yap, MBBS, PhD

Affiliation: M.D. Anderson Cancer Center

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: